Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-004422-42
    Sponsor's Protocol Code Number:ESKETINSUI2002
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-10-10
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-004422-42
    A.3Full title of the trial
    A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Subjects Assessed to be at Imminent Risk for Suicide
    Uno studio randomizzato, in doppio cieco, controllato con placebo psicoattivo per valutare l’efficacia e la sicurezza di tre dosi fisse (28 mg, 56 mg e 84 mg) di esketamine intranasale in aggiunta alla terapia standard completa per la rapida riduzione dei sintomi del disturbo depressivo maggiore, inclusa l’ideazione suicidaria, in soggetti pediatrici considerati a rischio imminente di suicidio
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study of the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Pediatric Patients at Imminent Risk for Suicide
    Uno studio per valutare l’efficacia e la sicurezza di esketamine intranasale per la rapida riduzione dei sintomi del disturbo depressivo maggiore in soggetti pediatrici considerati a rischio imminente di suicidio
    A.4.1Sponsor's protocol code numberESKETINSUI2002
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/020/2017
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen-Cilag International NV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Research & Development
    B.4.2CountryUnited States
    B.4.1Name of organisation providing supportJANSSEN CILAG INTERNATIONAL NV
    B.4.2CountryBelgium
    B.4.1Name of organisation providing supportJANSSEN CILAG SPA
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationJanssen-Cilag International NV
    B.5.2Functional name of contact pointClinical Registry Group
    B.5.3 Address:
    B.5.3.1Street AddressAchimedesweg 29
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333CM
    B.5.3.4CountryNetherlands
    B.5.6E-mailClinicalTrialsEU@its.jnj.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEsketamine - Nasal Solution - eq 140mg/mL esketamine base (eq 161.4 mg/mL esketamine HCl)
    D.3.4Pharmaceutical form Nasal spray, solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPNasal use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEsketamine (for (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone)
    D.3.9.3Other descriptive nameESKETAMINE HYDROCHLORIDE
    D.3.9.4EV Substance CodeSUB25811
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number140
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Midazolam-ratiopharm
    D.2.1.1.2Name of the Marketing Authorisation holderRatiopharm GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMidazolam
    D.3.4Pharmaceutical form Oral solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMIDAZOLAM HYDROCHLORIDE
    D.3.9.1CAS number 59467-96-8
    D.3.9.4EV Substance CodeSUB03289MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboNasal spray, solution
    D.8.4Route of administration of the placeboNasal use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboOral solution
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Major Depressive Disorder with Imminent Risk of Suicide
    Disturbo depressivo maggiore (MDD in inglese) con rischio imminente di suicidio
    E.1.1.1Medical condition in easily understood language
    Depression with Risk of Suicide
    Depressione con rischio di suicidio
    E.1.1.2Therapeutic area Psychiatry and Psychology [F] - Mental Disorders [F03]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10042458
    E.1.2Term Suicidal ideation
    E.1.2System Organ Class 10037175 - Psychiatric disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10057840
    E.1.2Term Major depression
    E.1.2System Organ Class 10037175 - Psychiatric disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10012397
    E.1.2Term Depression suicidal
    E.1.2System Organ Class 10037175 - Psychiatric disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10065604
    E.1.2Term Suicidal behaviour
    E.1.2System Organ Class 10037175 - Psychiatric disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to assess the efficacy of a single (first) dose of 3 fixed doses of intranasal esketamine (28 mg, 56 mg, and 84 mg) compared with psychoactive placebo (oral midazolam) in rapidly reducing the symptoms of MDD, including suicidal ideation, in subjects 12 to <18 years of age who are assessed to be at imminent risk for suicide. Efficacy will be assessed by the change from baseline in Children’s Depression Rating Scale, Revised (CDRS-R)
    total score at 24 hours post first dose (Day 2).
    L’obiettivo primario è la valutazione dell’efficacia di una singola (prima) dose tra tre dosi fisse di esketamine intranasale (28 mg, 56 mg e 84 mg) rispetto al placebo psicoattivo (midazolam orale) in termini di rapida riduzione dei sintomi dell’MDD, inclusa l’ideazione suicidaria, in soggetti di età compresa tra 12 e <18 anni considerati a rischio imminente di suicidio. L’efficacia sarà valutata in base alla variazione del punteggio totale della scala CDRS-R (Children’s Depression Rating Scale, Revised) dal basale a 24 ore dopo la prima dose (Giorno 2)
    E.2.2Secondary objectives of the trial
    -To evaluate the dose response of intranasal esketamine compared with psychoactive placebo in reducing the symptoms of MDD, including suicidal ideation, as assessed by the change from baseline in CDRS-R total score at 24 hours post first dose (Day 2) and at Day 25.
    -To evaluate the efficacy of single and repeated doses of intranasal esketamine compared with psychoactive placebo in reducing symptoms of suicidal ideation, as assessed by the Clinical Global Impression of Severity of Suicidality, revised version (CGI-SS-R) from the Suicide Ideation and Behavior Assessment Tool (SIBAT) at 4 hours and 24 hours post first dose and through the end of the double-blind treatment phase (Day 25).
    -To evaluate the efficacy of single and repeated doses of intranasal esketamine compared with psychoactive placebo in reducing symptoms of MDD
    -For more information on secondary objectives see Protocol section 2.1.1
    - Valutare la risposta alla dose di esketamine intranasale rispetto al placebo psicoattivo in termini di riduzione dei sintomi dell’MDD, inclusa l’ideazione suicidaria, in base alla variazione del punteggio totale CDRS-R dal basale a 24 ore dopo la prima dose (Giorno 2) e al Giorno 25
    - Valutare l’efficacia di dosi singole e ripetute di esketamine intranasale rispetto al placebo psicoattivo in termini di riduzione dei sintomi di ideazione suicidaria in base alla scala CGI-SS-R (Clinical Global Impression of Severity of Suicidality, versione rivista) dello strumento SIBAT (Suicide Ideation and Behavior Assessment Tool) 4 ore e 24 ore dopo la prima dose e fino al termine della fase di trattamento in doppio cieco (Giorno 25)
    - Valutare l’efficacia di dosi singole e ripetute di esketamine intranasale rispetto al placebo psicoattivo in termini di riduzione dei sintomi dell’MDD
    - Per maggiori informazioni sugli obiettivi secondari vedere la sezione 2.1.1 del protocollo
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male and female adolescents (12 to <18 years of age)
    2. Subject must meet DSM-5 diagnostic criteria for MDD, without psychotic features, based upon clinical assessment and confirmed by the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI KID).
    3. Subject must have current suicidal thinking with intent at the time of screening, confirmed by “Yes” responses to both MINI-KID Question B3 (Think about hurting yourself with the possibility that you might die. Or did you think about killing yourself?) AND Question B10 (Expect to go through with a plan to kill yourself?).
    4. In the physician’s opinion, acute psychiatric hospitalization is clinically warranted due to subject’s imminent risk of suicide.
    5. Subject must have a CDRS-R total score of ≥ 58 predose on Day 1.
    6. As part of standard of care treatment, subject must agree to be hospitalized voluntarily for a recommended period of 5 days after randomization (may be shorter or longer if clinically warranted in the investigator’s opinion).
    7. As part of the newly initiated or optimized standard of care treatment, subject must agree to take one of the prescribed non-investigational antidepressants medications (fluoxetine, escitalopram, sertraline) at least during the double-blind treatment phase (Day 25).
    8. As part of standard of care treatment, subject must agree to participate in a specific psychological intervention (individual cognitive behavioral therapy [CBT], interpersonal therapy, family therapy or psychodynamic psychotherapy) at least through the initial 8-week post-treatment follow-up period (Day 81).
    9. Subject is comfortable with self-administration of intranasal medication and able to follow instructions provided.
    10. Subject must be medically stable on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening. If there are abnormalities, the subject may be included only if the investigator judges the abnormalities to be not clinically significant. This determination must be recorded in the subject's source documents and initialed by the investigator.
    11. Subject must be medically stable on the basis of clinical laboratory tests performed by the local laboratory at screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the subject's source documents and initialed by the investigator.
    12. During the double-blind treatment phase and for at least 6 weeks after the last dose of study drug, contraception is required. Sexual abstinence is strongly recommended; however heterosexually active female subjects must practice a highly effective method of contraception (failure rate of <1% per year when used consistently and correctly).
    13. A female subject of childbearing potential must have a negative urine pregnancy test at screening, baseline, and end of double-blind phase.
    14. Subject must be willing and able to participate in all study activities and to adhere to the prohibitions and restrictions specified in this protocol (Section 4.3).
    15. Subject’s parent (or legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and is willing to allow the subject to participate in the study. Assent is also required of subjects as described in Section 16.2.3, Informed Consent and Assent.
    16. Subject’s parent (or legally acceptable representative) must sign a separate informed consent form if he or she agrees to provide an optional DNA sample for research (where local regulations permit). Refusal to give consent for the optional DNA research sample does not exclude a subject from participation in the study.

    For further information on inclusion criteria see protocol section 4.1.
    E.3 Criteri di inclusione principali (elencare i più importanti):
    1.Adolescenti di sesso maschile e femminile (da 12 a <18 anni di età)
    2.Il soggetto deve soddisfare i criteri diagnostici DSM-5 per l’MDD, senza caratteristiche psicotiche, in base alla valutazione clinica, che deve essere confermata dal questionario MINI-KID (Mini International Neuropsychiatric Interview per bambini e adolescenti).
    3.Il soggetto deve presentare pensieri suicidi attuali con intento al momento dello screening, confermati dalle risposte “Sì” alla domanda B3 (Pensi di ferirti con la possibilità di morire? O hai pensato di ucciderti?) E alla domanda B10 (Pensi di portare a termine il piano di ucciderti?) del questionario MINI-KID.
    4.Il medico deve ritenere clinicamente giustificato il ricovero psichiatrico acuto a causa del rischio imminente di suicidio del soggetto.
    5.Il soggetto deve presentare un punteggio totale CDRS-R ≥ 58 prima della dose del Giorno 1.
    6.Nel quadro della terapia standard, il soggetto deve accettare il ricovero volontario per un periodo consigliato di cinque giorni dopo la randomizzazione (il periodo potrà essere più breve o più lungo se clinicamente giustificato, secondo il giudizio dello sperimentatore).
    7.Nel quadro della terapia standard appena iniziata o ottimizzata, il soggetto deve accettare di assumere una delle terapie antidepressive non sperimentali prescritte (fluoxetina, escitalopram, sertralina) durante la fase di trattamento in doppio cieco (Giorno 25).
    8.Nel quadro della terapia standard, il soggetto deve accettare di partecipare a un intervento psicologico specifico (terapia cognitivo-comportamentale [CBT] individuale, terapia interpersonale, terapia familiare o psicoterapia psicodinamica) almeno nel corso del periodo di follow-up iniziale di 8 settimane (Giorno 81).
    9.Il soggetto è a suo agio con l'auto-somministrazione del farmaco intranasale ed è in grado di seguire le istruzioni fornite.
    10.Il soggetto deve presentare una condizione medica stabile definita sulla base dei risultati dell’ esame obiettivo, anamnesi, segni vitali, ed ECG a 12 derivazioni, ottenuti allo screening. Se vengono riscontrate anomalie, il soggetto può essere incluso nello studio se lo sperimentatore giudica tale anomalia non clinicamente significativa. Questa decisione deve essere registrata nei documenti originali del paziente e sottoscritta dallo sperimentatore.
    11.Il soggetto deve presentare una condizione medica stabile definita sulla base dei test clinici effettuati dal laboratorio locale allo screening. Se i risultati delle analisi sierologiche, delle analisi ematologiche o delle analisi delle urine non rientrano nei normali intervalli di riferimento, il soggetto può essere incluso soltanto se lo sperimentatore ritiene che le anomalie o deviazioni dalla norma non siano clinicamente significative. Questa decisione deve essere registrata nei documenti originali del paziente e sottoscritta dallo sperimentatore.
    12.Durante la fase di doppio cieco e per almeno 6 settimane dopo l’ultima dose assunta del farmaco in studio è richiesta la contraccezione. L’astinenza sessuale è fortemente raccomandata; tuttavia i soggetti eterosessuali di sesso femminile devono praticare un metodo di contraccezione altamente efficace (con percentuale di fallimento < 1% all’anno quando utilizzato in modo coerente e corretto)
    13.Le donne potenzialmente fertili devono presentare un test di gravidanza sulle urine negativo allo screening, alla visita basale e alla fine della fase in doppio cieco.
    14.Il soggetto deve essere disposto e in grado di partecipare a tutte le attività di studio e a seguire i divieti e le restrizioni specificate in questo protocollo (sezione 4.3).
    15.Il genitore del soggetto (o il legale rappresentante) deve firmare un Modulo di Consenso Informato (ICF) nel quale si indica che lui o lei comprende lo scopo e le procedure richieste per lo studio ed è disposto ad acconsentire che il soggetto partecipi allo studio.
    È richiesto anche l'assenso di soggetti come descritto nella sezione 16.2.3 del protocollo “Informed Consent and Assent”
    16.Il genitore del soggetto (o il legale rappresentante) deve firmare un Modulo di Consenso Informato separato nel caso lui o lei siano d’accordo a fornire un campione di sangue per la ricerca opzionale sul DNA
    Il rifiuto a dare il consenso per la partecipazione a tale ricerca non preclude la partecipazione del soggetto allo studio.
    Per ulteriori informazioni sui criteri di inclusione vedere la sezione 4.1 del Protocollo.
    E.4Principal exclusion criteria
    1. Subject has a current DSM-5 diagnosis of bipolar (or related disorders), intellectual disability, autism spectrum disorder, conduct disorder, anorexia nervosa, oppositional defiant disorder, or obsessive compulsive disorder.
    2. Subject currently meets DSM-5 criteria for borderline personality disorder.
    Subjects not meeting full DSM-5 criteria for borderline personality disorder but exhibiting recurrent suicidal gestures, threats, or self-mutilating behaviors should also be excluded.
    3. Subject has a current or prior DSM-5 diagnosis of a psychotic disorder or MDD with psychosis.
    4. Subject meets the DSM-5 severity criteria for moderate or severe substance or alcohol use disorder (except for nicotine or caffeine) within the 6 months before screening.
    5. Subject has a history of seizure disorder.
    6. Subject has a history or current signs and/or symptoms of liver or renal insufficiency; has a current diagnosis of clinically significant cardiac (eg, congenital heart disease, cardiomyopathy, or tachyarrhythmias), vascular, pulmonary, gastrointestinal, endocrine (including uncontrolled hyperthyroidism), neurologic, hematologic, rheumatologic, or metabolic (including severe dehydration/hypovolemia) disease based on investigator judgment.
    7. Subject has uncontrolled hypertension (SBP and/or DBP that is greater than or equal to the 95th percentile for sex, age, and height) despite diet, exercise or a stable dose of an allowed anti-hypertensive treatment at screening; or any past history of hypertensive crisis. See Attachment 2 for pediatric blood pressure tables with percentile ranking by age, sex, and height for determination of hypertensive status.
    8. Subject has a positive urine test result(s) for phencyclidine (PCP), cocaine, methamphetamines, or amphetamines/3,4-methylenedioxy-methamphetamine (MDMA) at screening. Subjects known to be using heroin should be excluded from the study.
    9. Subject has a history of malignancy within 5 years before screening, with the exception of a malignancy that, in the opinion of the investigator and in concurrence with the sponsor's medical monitor, is considered to have minimal risk of recurrence.
    10. Subject has anatomical or medical conditions that may impede delivery or absorption of intranasal study medication.
    11. Subject has an abnormal or deviated nasal septum with any 1 or more of the following symptoms: blockage of 1 or both nostrils, nasal congestion (especially 1-sided), frequent nosebleeds, and frequent sinus infections (and at times has facial pain, headaches, and postnasal drip with the sinus infection).
    12. Subject has known allergies, hypersensitivity, intolerance or contraindications to midazolam, esketamine or ketamine, or their excipients.
    13. Subject has taken any disallowed therapy(ies) as noted in Section 8, Prestudy and Concomitant Therapy and Attachment 1.
    14. Subject has received an investigational drug (including esketamine, ketamine, or investigational vaccines) or used an invasive investigational medical device within 60 days before the first dose of study drug or is currently enrolled in an investigational study.
    15. Subject is a female who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study drug.
    16. Subject has any situation or condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
    17. Subject, parent or legal guardian is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.

    For further information on exclusion criteria see protocol section 4.2.
    E.4 Criteri di esclusione principali (elencare i più importanti):

    1.Il soggetto presenta attualmente una diagnosi DSM-5 di disturbo bipolare (o disturbi correlati), disabilità intellettiva, disturbo dello spettro autistico, disturbo del comportamento, anoressia nervosa, disturbo oppositivo provocatorio o disturbo ossessivo compulsivo.
    2.Il soggetto soddisfa attualmente i criteri DSM-5 per il disturbo borderline di personalità. Vanno esclusi anche i soggetti che non soddisfano completamente i criteri DSM-5 per il disturbo borderline di personalità ma mostrano gesti suicidi, minacce o comportamenti di automutilazione.
    3.Il soggetto presenta una diagnosi DSM-5 attuale o pregressa di disturbo psicotico o MDD con psicosi.
    4.Il soggetto rispetta i criteri gravi del DSM-V per l’abuso moderato o grave di sostanze o alcol, abuso di esketamine ad eccezione di nicotina o caffeina, nei sei mesi precedenti allo screening.
    5.Il soggetto ha una storia di crisi epilettiche.
    6.Il soggetto ha presentato in passato o presenta al momento segni e/o sintomi di insufficienza epatica o renale o di clinicamente significativi disturbi cardiaci (scompenso cardiaco, cardiomiopatia o tachicardia), vascolari, polmonari, gastrointestinali, endocrini (inclusa deidratazione grave/ipovolemia), neurologici, ematologici, reumatologici o metabolici, secondo il giudizio dello sperimentatore.
    7.Il soggetto presenta ipertensione non controllata (pressione sistolica (SBP) e/o pressione diastolica (DBP) media pari o superiore al 95° percentile per sesso, età e altezza) nonostante la dieta, l’esercizio fisico o una dose stabile di una terapia antipertensiva consentita allo screening o ha sofferto in passato di crisi ipertensiva. Per stabilire lo stato ipertensivo, consultare l’Allegato 2 contenente le tabelle sulla pressione sanguigna pediatrica con classificazione dei percentili per età, sesso e altezza.
    8.Il soggetto che allo screening presenta un test delle urine positivo alla fenciclidina (PCP), cocaina, metanfetamina, o anfetamina/3,4 metilenediossimetanfetamina (MDMA). I soggetti di cui si conosce l’utilizzo di eroina sono esclusi dallo studio.
    9.Il soggetto che ha avuto un tumore maligno nei 5 anni precedenti lo screening, a meno che a giudizio dello sperimentatore e in accordo con il monitor dello sponsor, il rischio di recidiva sia considerato minimo.
    10.Il soggetto presenta una condizione anatomica o medica che potrebbe impedire la somministrazione o l’assorbimento del farmaco sperimentale intranasale.
    11.Il soggetto ha il setto nasale anomalo o deviato con uno o più dei seguenti sintomi: ostruzione di una o entrambe le narici, congestione nasale (soprattutto da un lato), frequenti emorragie nasali, e frequenti sinusiti (e con la sinusite a volte ha dolori facciali, mal di testa e gocciolamenti dal naso)
    12.Soggetti che abbiano allergie, ipersensibilità, intolleranza o controindicazioni al midazolam, all’esketamine o alla ketamine o ai loro eccipienti.
    13.Il soggetto che ha assunto terapie non ammesse riportate nella sezione 8 del protocollo “Prestudy and Concomitant Therapy” e nell’allegato 1.
    14.Il soggetto che ha assunto un farmaco sperimentale (inclusa esketamine, ketamine o vaccini sperimentali) o che ha utilizzato un device sperimentale invasivo nei 60 giorni precedenti all’assunzione delle prima dose del farmaco dello studio o un soggetto che sta partecipando ad un altro studio clinico.
    15.Il soggetto di sesso femminile è in stato di gravidanza, in allattamento o sta pensando ad una gravidanza mentre sta partecipando allo studio o entro 3 mesi successivi l’assunzione dell’ultima dose del farmaco in studio.
    16.Il soggetto che abbia a giudizio dello sperimentatore una qualche situazione o condizione per la quale la sua partecipazione allo studio non sarebbe nel suo miglior interesse (per esempio che ne compromettessero il benessere) o che potrebbe impedire, limitare o rendere poco chiare le valutazioni specificate dal protocollo.
    17.Il soggetto per il quale il genitore o il tutore legale sia alle dipendenze dello sperimentatore o del centro in cui si svolge lo studio, con un’implicazione diretta nello studio stesso o in altri studi che sono condotti dallo stesso sperimentatore o dal centro, così come membri della famiglia dello sperimentatore o dei suoi dipendenti
    Per ulteriori informazioni sui criteri di inclusione vedere la sezione 4.2 del Protocollo.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy evaluation will be the change from baseline (Day 1, predose) in depressive symptoms, including suicidal ideation, as measured by the CDRS-R total score.
    L’efficacia primaria sarà valutata in base alla variazione del punteggio totale della scala CDRS-R (Children’s Depression Rating Scale, Revised) dal basale (Giorno 1, pre-dose) per i sintomi depressivi inclusa l’ideazione suicidaria.
    E.5.1.1Timepoint(s) of evaluation of this end point
    24 hours post first dose
    24 ore dopo la prima dose
    E.5.2Secondary end point(s)
    1.) Dose response as assessed by CDRS-R
    2.) Change from baseline in CDRS-R
    3.) Change from baseline in MADRS
    4.) Change from baseline in CGI-SS-R from SIBAT
    5.) Change from baseline in SIBAT
    6.) Change from baseline in CDI 2:SR [S]

    For additional endpoints, see protocol section 2.1.2.
    1.) Risposta alla dose attraverso il punteggio CDRS-R;2.) Variazione dal basale del punteggio CDRS-R;3.) Variazione dal basale del punteggio MADRS;4.) Variazione dal basale del punteggio CGI-SS-R dalla SIBAT
    5.) Variazione dal basale del punteggio SIBAT;6.) Variazione dal basale del punteggio CDI 2:SR [S]
    E.5.2.1Timepoint(s) of evaluation of this end point
    1.) 24 hours post first dose
    2.) Post single/repeated doses, at 4 hours post first dose, through the end of the double-blind treatment phase, and during the 6-month post-treatment follow-up phase.
    3.) Post single/repeated doses, at 4 hours and 24 hours post first dose, through the end of the double-blind treatment phase, and during the 6-month post-treatment follow-up phase.
    4.) Post single/repeated doses at 4 hours and 24 hours post first dose, through the end of the double-blind treatment phase (Day 25).
    5.) Post single/repeated doses, through the end of the double-blind treatment phase (Day 25) and during the 6-month post-treatment follow-up phase
    6.) Post single/repeated doses, at 24 hours post first dose and through the end of the double-blind treatment phase (Day 25).
    1.) 24 ore dopo prima dose
    2.) dopo dosi singole e ripetute, 4 ore dopo prima dose, fino al termine della fase di trattamento in doppio cieco e durante la fase di follow-up post-trattamento di 6 mesi
    3.) dopo dosi singole e ripetute, 4 ore e 24 ore dopo la prima dose, fino al termine della fase di trattamento in doppio cieco e durante la fase di follow-up post-trattamento.
    4.) dopo dosi singole e ripetute, 4 ore e 24 ore dopo la prima dose, fino al termine della fase di trattamento in doppio cieco (day 25)
    5.) dopo dosi singole e ripetute, fino al termine della fase di trattamento in doppio cieco (day 25) e durante la fase di follow-up post-trattamento.
    6.) dopo dosi singole e ripetute, 24 ore dopo la prima dose e fino al termine della fase di trattamento in doppio cieco (day 25)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Double dummy
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    psychoactive placebo (midazolam)
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA22
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Brazil
    Bulgaria
    France
    Hungary
    Italy
    Poland
    Spain
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days24
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days24
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 145
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 145
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state18
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 79
    F.4.2.2In the whole clinical trial 145
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The study investigator must ensure the subject is appropriately transitioned and/or followed for any additional care required. Subjects should continue with their standard of care after the end of the study per investigator's or
    the treating physician's clinical judgement. This should be planned for in advance of each patient's completion of the study and based on their individual clinical needs.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-10-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-11-14
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 12:19:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA